Synopsis
Synopsis
0
JDMF
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 67555, R
2. Alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2h-1-benzopyran-2-methanol
3. Bystolic
4. Hydrochloride, Nebivolol
5. Lobivon
6. Nebilet
7. Nebivolol
8. R 67555
9. R-67555
10. R67555
11. Silostar
1. 169293-50-9
2. Nebivolol Hcl
3. 2,2'-azanediylbis(1-(6-fluorochroman-2-yl)ethanol) Hydrochloride
4. 152520-56-4
5. Rac Nebivolol Hydrochloride
6. R 065824 Hydrochloride
7. Nebilox
8. Rac-nebivolol Hcl
9. R-067555
10. Schembl514784
11. N-phenyliminodiaceticacid
12. Chembl1201731
13. Akos016006035
14. Ac-4233
15. Ac-5636
16. Ccg-214847
17. Ro67555
18. As-12100
19. Cs-0362720
20. Ft-0652243
21. Ft-0655833
22. 520n564
23. W-60374
24. J-010524
25. 1-(6-fluoro-3,4-dihydro-2h-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2h-chromen-2-yl)-2-hydroxyethyl]amino]ethanol;hydrochloride
26. 2h-1-benzopyran-2-methanol,a,a'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-,hydrochloride(1:1)
27. Alpha,alpha'[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2h-1-benzopyran-2-methanol]hydrochloride
| Molecular Weight | 441.9 g/mol |
|---|---|
| Molecular Formula | C22H26ClF2NO4 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 6 |
| Exact Mass | 441.1518423 g/mol |
| Monoisotopic Mass | 441.1518423 g/mol |
| Topological Polar Surface Area | 71 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 483 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 4 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Adrenergic beta-1 Receptor Agonists
Compounds that bind to and activate ADRENERGIC BETA-1 RECEPTORS. (See all compounds classified as Adrenergic beta-1 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Rampex Labs – Simplifying Synthesis with Innovation, Quality, and Commitment to Global Pharmaceutical Excellence.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-01-05
Pay. Date : 2014-10-07
DMF Number : 28627
Submission : 2014-09-10
Status : Active
Type : II
Date of Issue : 2025-09-03
Valid Till : 2028-09-02
Written Confirmation Number : WC-0362
Address of the Firm :
NDC Package Code : 69037-0004
Start Marketing Date : 2007-12-17
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30052
Submission : 2015-12-03
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35332
Submission : 2021-10-28
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the acquisition of Nebivolol HCl, targeting the Beta-2 adrenergic receptor, the deal aims to advance hypertension treatment.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Senores Pharmaceuticals
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Senores Pharmaceuticals
Deal Size : $1.6 million
Deal Type : Acquisition
Senores Pharmaceuticals Acquiring Apnar Pharma and Five ANDAs
Details : Through the acquisition of Nebivolol HCl, targeting the Beta-2 adrenergic receptor, the deal aims to advance hypertension treatment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nebivolol Tablets 5 mg Relative to Nebilet Tablets 5 mg
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Lead Product(s): Nebivolol,Ramipril
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Ramipril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Lead Product(s): Nebivolol,Amlodipine
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 24, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 24, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zofenopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Lead Product(s): Zofenopril,Nebivolol
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zofenopril,Nebivolol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zofenopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glaucoma, Open-Angle.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Trial Runners, LLC | Summit Analytical LLC
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Trial Runners, LLC | Summit Analytical LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glaucoma, Open-Angle.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DWN12088 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Lead Product(s): DWN12088,Nebivolol
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 17, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DWN12088,Nebivolol
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DWN12088 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 17, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2018

Details:
Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Heart Failure.
Lead Product(s): Nebivolol,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Menarini
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2015

Lead Product(s) : Nebivolol,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Menarini
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nebivolol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 02, 2015

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
NEBIVOLOL HYDROCHLORIDE; VALSARTAN
Brand Name : BYVALSON
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE;80MG
Packaging :
Approval Date : 2016-06-03
Application Number : 206302
Regulatory Info : DISCN
Registration Country : USA
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : PRESCRIPTION
Registration Country : Canada
NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE)
Brand Name : BYSTOLIC
Dosage Form : TABLET
Dosage Strength : 2.5MG
Packaging :
Approval Date :
Application Number : 2398990
Regulatory Info : PRESCRIPTION
Registration Country : Canada
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : PRESCRIPTION
Registration Country : Canada
NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE)
Brand Name : BYSTOLIC
Dosage Form : TABLET
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number : 2399008
Regulatory Info : PRESCRIPTION
Registration Country : Canada
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : PRESCRIPTION
Registration Country : Canada
NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE)
Brand Name : BYSTOLIC
Dosage Form : TABLET
Dosage Strength : 10MG
Packaging : 30
Approval Date :
Application Number : 2399016
Regulatory Info : PRESCRIPTION
Registration Country : Canada
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : PRESCRIPTION
Registration Country : Canada
NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE)
Brand Name : BYSTOLIC
Dosage Form : TABLET
Dosage Strength : 20MG
Packaging : 30
Approval Date :
Application Number : 2399024
Regulatory Info : PRESCRIPTION
Registration Country : Canada
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : BYSTOLIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Packaging :
Approval Date : 2007-12-17
Application Number : 21742
Regulatory Info : RX
Registration Country : USA
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : BYSTOLIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Packaging :
Approval Date : 2007-12-17
Application Number : 21742
Regulatory Info : RX
Registration Country : USA
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : BYSTOLIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 10MG BASE
Packaging :
Approval Date : 2007-12-17
Application Number : 21742
Regulatory Info : RX
Registration Country : USA
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : BYSTOLIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 20MG BASE
Packaging :
Approval Date : 2008-10-08
Application Number : 21742
Regulatory Info : RX
Registration Country : USA
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Nebivolol \"Orion\"
Dosage Form : Tablet
Dosage Strength : 5mg
Packaging :
Approval Date : 12-12-2007
Application Number : 28104095707
Regulatory Info : Prescription
Registration Country : Denmark
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
NEBIVOLOL HYDROCHLORIDE; VALSARTAN
Brand Name : BYVALSON
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE;80MG
Approval Date : 2016-06-03
Application Number : 206302
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : BYSTOLIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Approval Date : 2007-12-17
Application Number : 21742
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : BYSTOLIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Approval Date : 2007-12-17
Application Number : 21742
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : BYSTOLIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 10MG BASE
Approval Date : 2007-12-17
Application Number : 21742
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : BYSTOLIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 20MG BASE
Approval Date : 2008-10-08
Application Number : 21742
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD : No
TE Code : AB
Brand Name : NEBIVOLOL HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2.5MG BASE
Approval Date : 2022-11-14
Application Number : 216172
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD : No
TE Code : AB
Brand Name : NEBIVOLOL HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Approval Date : 2022-11-14
Application Number : 216172
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD : No
TE Code : AB
Brand Name : NEBIVOLOL HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 10MG BASE
Approval Date : 2022-11-14
Application Number : 216172
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
RLD : No
TE Code : AB
Brand Name : NEBIVOLOL HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 20MG BASE
Approval Date : 2022-11-14
Application Number : 216172
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : NEBIVOLOL HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Approval Date : 2017-05-25
Application Number : 203821
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
RX/OTC/DISCN :
Dosage Form : Tablets
Dosage Strength : 5 mg
Price Per Pack (Euro) : 6.1
Published in :
Country : Italy
RX/OTC/DISCN :
Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablet
Dosage Strength : 5mg+25mg
Price Per Pack (Euro) : 5.97
Published in :
Country : Italy
RX/OTC/DISCN :

Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablet
Dosage Strength :
Price Per Pack (Euro) : 5.97
Published in :
Country : Italy
RX/OTC/DISCN :

Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablets
Dosage Strength : 5 mg/12.5 mg
Price Per Pack (Euro) : 5.97
Published in :
Country : Italy
RX/OTC/DISCN :

Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablets
Dosage Strength : 5 mg/25 mg
Price Per Pack (Euro) : 5.97
Published in :
Country : Italy
RX/OTC/DISCN :

Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablets
Dosage Strength : 5 mg/12.5 mg
Price Per Pack (Euro) : 8.18
Published in :
Country : Italy
RX/OTC/DISCN :

Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablets
Dosage Strength : 5 mg/12.5 mg
Price Per Pack (Euro) : 8.18
Published in :
Country : Italy
RX/OTC/DISCN :

Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablets
Dosage Strength : 5 mg/12.5 mg
Price Per Pack (Euro) : 8.18
Published in :
Country : Italy
RX/OTC/DISCN :

Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablets
Dosage Strength : 5 mg/25 mg
Price Per Pack (Euro) : 8.18
Published in :
Country : Italy
RX/OTC/DISCN :

Nebivolol; Hydrochlorothiazide
Dosage Form : Film-Coated Tablets
Dosage Strength : 5 mg/25 mg
Price Per Pack (Euro) : 8.18
Published in :
Country : Italy
RX/OTC/DISCN :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-10-04
NEBIVOLOL HYDROCHLORIDE; VALSARTAN
US Patent Number : 7838552
Drug Substance Claim :
Drug Product Claim :
Application Number : 206302
Patent Use Code : U-185
Delist Requested :
Patent Use Description : METHOD OF TREATING HYP...
Patent Expiration Date : 2027-10-04
Patent Expiration Date : 2026-08-29
NEBIVOLOL HYDROCHLORIDE; VALSARTAN
US Patent Number : 7803838
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 206302
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-08-29
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
Nebivolol Hydrochloride (150 mg)
CAS Number : 152520-56-4
Quantity Per Vial : 150
Sale Unit : mg
Price : $1,450. 00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1457833 / F027M0

Nebivolol Related Compound A (30 mg) (See USP...
CAS Number :
Quantity Per Vial : 30
Sale Unit : mg
Price : $877.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1457855 / F027N0

Nebivolol Related Compound B (30 mg) (See USP...
CAS Number :
Quantity Per Vial : 30
Sale Unit : mg
Price : $877.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1457866 / F027P0

Nebivolol Related Compound C (100 mg) (COLD S...
CAS Number : 876514-31-7
Quantity Per Vial : 100
Sale Unit : mg
Price : $877.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1457877 / F027Q0

Nebivolol Related Compound D (100 mg) ((RS)-6...
CAS Number : 793669-26-8
Quantity Per Vial : 100
Sale Unit : mg
Price : $814.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1457888 / F027R0

Nebivolol Related Compound E (30 mg) (1-(Chro...
CAS Number :
Quantity Per Vial : 30
Sale Unit : mg
Price : $814.00
Details : Material Origin- Chemical Synthesis; USMCA- N...
Monograph :
Storage :
Code/Batch No : Catalog #1457899 / F027S0

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ANALYTICAL
ABOUT THIS PAGE
14
PharmaCompass offers a list of Nebivolol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nebivolol manufacturer or Nebivolol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nebivolol manufacturer or Nebivolol supplier.
A Nebivolol HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nebivolol HCl, including repackagers and relabelers. The FDA regulates Nebivolol HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nebivolol HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nebivolol HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Nebivolol HCl supplier is an individual or a company that provides Nebivolol HCl active pharmaceutical ingredient (API) or Nebivolol HCl finished formulations upon request. The Nebivolol HCl suppliers may include Nebivolol HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Nebivolol HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Nebivolol HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Nebivolol HCl active pharmaceutical ingredient (API) in detail. Different forms of Nebivolol HCl DMFs exist exist since differing nations have different regulations, such as Nebivolol HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nebivolol HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Nebivolol HCl USDMF includes data on Nebivolol HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nebivolol HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nebivolol HCl suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Nebivolol HCl Drug Master File in Korea (Nebivolol HCl KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Nebivolol HCl. The MFDS reviews the Nebivolol HCl KDMF as part of the drug registration process and uses the information provided in the Nebivolol HCl KDMF to evaluate the safety and efficacy of the drug.
After submitting a Nebivolol HCl KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Nebivolol HCl API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Nebivolol HCl suppliers with KDMF on PharmaCompass.
A Nebivolol HCl CEP of the European Pharmacopoeia monograph is often referred to as a Nebivolol HCl Certificate of Suitability (COS). The purpose of a Nebivolol HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Nebivolol HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Nebivolol HCl to their clients by showing that a Nebivolol HCl CEP has been issued for it. The manufacturer submits a Nebivolol HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Nebivolol HCl CEP holder for the record. Additionally, the data presented in the Nebivolol HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Nebivolol HCl DMF.
A Nebivolol HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Nebivolol HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Nebivolol HCl suppliers with CEP (COS) on PharmaCompass.
A Nebivolol HCl written confirmation (Nebivolol HCl WC) is an official document issued by a regulatory agency to a Nebivolol HCl manufacturer, verifying that the manufacturing facility of a Nebivolol HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Nebivolol HCl APIs or Nebivolol HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Nebivolol HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Nebivolol HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nebivolol HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nebivolol HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nebivolol HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nebivolol HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nebivolol HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nebivolol HCl suppliers with NDC on PharmaCompass.
Nebivolol HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nebivolol HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nebivolol HCl GMP manufacturer or Nebivolol HCl GMP API supplier for your needs.
A Nebivolol HCl CoA (Certificate of Analysis) is a formal document that attests to Nebivolol HCl's compliance with Nebivolol HCl specifications and serves as a tool for batch-level quality control.
Nebivolol HCl CoA mostly includes findings from lab analyses of a specific batch. For each Nebivolol HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nebivolol HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Nebivolol HCl EP), Nebivolol HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nebivolol HCl USP).